JP2003534384A5 - - Google Patents

Download PDF

Info

Publication number
JP2003534384A5
JP2003534384A5 JP2001587795A JP2001587795A JP2003534384A5 JP 2003534384 A5 JP2003534384 A5 JP 2003534384A5 JP 2001587795 A JP2001587795 A JP 2001587795A JP 2001587795 A JP2001587795 A JP 2001587795A JP 2003534384 A5 JP2003534384 A5 JP 2003534384A5
Authority
JP
Japan
Prior art keywords
formulation
antagonist
agonist
peptide
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001587795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/016654 external-priority patent/WO2001091780A1/en
Publication of JP2003534384A publication Critical patent/JP2003534384A/ja
Publication of JP2003534384A5 publication Critical patent/JP2003534384A5/ja
Pending legal-status Critical Current

Links

JP2001587795A 2000-05-26 2001-05-23 神経保護性ペプチド Pending JP2003534384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20765400P 2000-05-26 2000-05-26
US60/207,654 2000-05-26
PCT/US2001/016654 WO2001091780A1 (en) 2000-05-26 2001-05-23 Neuroprotective peptides

Publications (2)

Publication Number Publication Date
JP2003534384A JP2003534384A (ja) 2003-11-18
JP2003534384A5 true JP2003534384A5 (https=) 2008-07-03

Family

ID=22771463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001587795A Pending JP2003534384A (ja) 2000-05-26 2001-05-23 神経保護性ペプチド

Country Status (11)

Country Link
EP (1) EP1296702A4 (https=)
JP (1) JP2003534384A (https=)
CN (1) CN1318084C (https=)
AU (2) AU7490401A (https=)
BR (1) BR0111182A (https=)
CA (1) CA2410453A1 (https=)
IL (1) IL153079A0 (https=)
MX (1) MXPA02011727A (https=)
NZ (1) NZ522924A (https=)
WO (1) WO2001091780A1 (https=)
ZA (1) ZA200210304B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077194A1 (en) 1999-06-14 2000-12-21 Genentech, Inc. A structured peptide scaffold for displaying turn libraries on phage
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
ATE428727T1 (de) 2003-05-12 2009-05-15 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
AU2004238868B2 (en) 2003-05-12 2010-01-21 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CN1820024B (zh) 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
CN101528263B (zh) 2006-06-30 2013-01-23 Sku资产管理有限公司 用于癌症的先天性免疫方法的缀合物
EP2118127A4 (en) 2007-01-31 2010-12-01 Affymax Inc NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
RU2683325C2 (ru) 2009-02-05 2019-03-28 Иммьюноджен, Инк. Новые производные бензодиазепина
RU2410392C2 (ru) 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf
WO2012003960A1 (en) 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
JP5826863B2 (ja) * 2011-02-15 2015-12-02 イミュノジェン・インコーポレーテッド 細胞傷害性ベンゾジアゼピン誘導体
CA2918223A1 (en) * 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
JP7445978B2 (ja) * 2018-09-14 2024-03-08 エポメッド株式会社 抗エリスロポエチン受容体ペプチド
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Similar Documents

Publication Publication Date Title
JP2003534384A5 (https=)
KR101160611B1 (ko) 폴리(에틸렌 글리콜)로 변형된 펩티드 기재 화합물용 신규 스페이서 부분
Pasut et al. PEGylation of proteins as tailored chemistry for optimized bioconjugates
EP1496926B1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP6073409B2 (ja) 組換えエリスロポエチンと部分的に組合されたil−1インヒビターおよびtnfアンタゴニストの貧血治療用途
TWI250988B (en) Thrombopoietic compounds
KR101352225B1 (ko) 신규한 엑센딘 변형 및 이들의 콘쥬게이트
US7030218B2 (en) Pseudo native chemical ligation
TW570802B (en) Improved interferon polymer conjugates
JP4157277B2 (ja) 実質的に純粋なヒスチジン結合タンパク質−ポリマー結合体
JP2005509609A5 (https=)
JPH10500693A (ja) 改変型インスリン様増殖因子
EA004791B1 (ru) Композиции на основе слитого белка ob и способы их применения
RS51852B (sr) Modifikovani peptidi kao terapeutski agensi
US20070166278A1 (en) Novel g-csf conjugates
US8906355B2 (en) Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof
CN102421447A (zh) 用peg标记干扰素的方法
KR100507796B1 (ko) 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
IL273368B2 (en) Composite medical preparations with increased binding capacity to albumin
TW201138831A (en) Modified granulocyte colony stimulating factor (G-CSF)
KR100459105B1 (ko) 변형된 인터페론-알파 2a 및 2b, 그리고 이들과 PEG유도체와의 배합체
Kang et al. In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats
ZA200505707B (en) Polymer conjugates of mutated neublastin
LT6164B (lt) Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN102724980B (zh) 蛋白-聚合物偶联物的治疗用途